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Bacterial stimuli activate nitric oxide colonic
mucosal production in diverticular disease.
Protective effects of L. casei DG
(Lactobacillus paracasei CNCM I-1572)
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Abstract
Background: Micro-inflammation and changes in gutmicrobiotamay play a role in the pathogenesis of diverticular disease (DD).
Objective: The objective of this article is to evaluate the expression of nitric oxide (NO)-related mediators and S100B in
colonic mucosa of patients with DD in an ex vivo model of bacterial infection.
Methods: Intestinal biopsies obtained from patients with diverticulosis, symptomatic uncomplicated diverticular disease
(SUDD) and SUDD with previous acute diverticulitis (SUDDþAD) were stimulated with the probiotic L. casei DG (LCDG) and/
or the pathogen enteroinvasive Escherichia coli (EIEC). S100B, NO release and iNOS expression were then evaluated.
Results: Basal iNOS expression was significantly increased in SUDD and SUDDþAD patients. Basal NO expression was
significantly increased in SUDDþAD. No differences in S100B release were found. In all groups, iNOS expression was
significantly increased by EIEC and reduced by LCDG. In all groups, except for SUDDþAD, EIEC significantly increased NO
release, whereas no increase was observed when LCDG was added to biopsies. EIEC did not induce significant changes in
S100B release.
Conclusions: Colonic mucosa of patients with DD is characterized by a different reactivity toward pathogenic stimuli. LCDG
plays a role in counteracting the pro-inflammatory effects exerted by EIEC, suggesting a beneficial role of this probiotic in
DD.
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Introduction
Diverticular disease (DD) of the colon is a common
clinical condition in the Western world. Its prevalence
in the general population is estimated to range between
20% and 60%, and this condition is one of the most
common gastrointestinal indications for hospital and
medical visits.1,2
Diverticula of the large bowel are out-pouchings of
the colon at weak points in the circular muscle where
blood vessels (vasa recta) penetrate to supply the
mucosa.3 The mere presence of diverticula is deﬁned
as diverticulosis. In about 20% of patients, the presence
of diverticula give rise to illness, ranging from a syn-
drome characterized by recurrent abdominal symptoms
– pain, bloating and changes in bowel habits in the
absence of macroscopically evident signs of acute
inﬂammation – deﬁned as symptomatic uncomplicated
diverticular disease (SUDD), to an acute inﬂammation
of colonic diverticula, deﬁned as acute diverticulitis
1Department of Clinical Medicine and Surgery, Federico II University of
Naples, Naples, Italy
2Sofar S.p.A. Trezzano Rosa, Italy
Corresponding author:
Rosario Cuomo, Department of Clinical Medicine and Surgery, Federico II
University Hospital School of Medicine, Via S. Pansini 5, Building 6, 80131
Napoli, Italy.
Email: rcuomo@unina.it
United European Gastroenterology Journal
2017, Vol. 5(5) 715–724
! Author(s) 2016
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/2050640616684398
journals.sagepub.com/home/ueg
(AD) with its typical complications (abscesses, stenoses,
ﬁstulas, perforations).4
Despite the signiﬁcant burden of the pathology, the
pathogenesis is poorly understood and several etiological
factors may play a role in the onset of this disease.5–7
Recently, changes in the intestinal microbiota have
been involved in the pathogenesis of symptoms and
related acute inﬂammation.8 Moreover, various studies
pointed out the role of the enteric nervous system
(ENS) in the pathophysiology of DD.7
In a recent study by our group, in a context of intes-
tinal inﬂammation, together with an increased indu-
cible nitric oxide (NO)-synthase (iNOS) expression
and NO release, we observed an increased release of
S100B, a protein speciﬁcally expressed and released
by enteric glial cells (EGCs).9 Previously, we demon-
strated that the intestinal mucosa of patients with
celiac disease and ulcerative colitis was more ‘‘sensi-
tive’’ to pro-inﬂammatory and infectious stimuli than
unaﬀected mucosa, and that EGCs participated in the
modulation of mucosal NO production via S100B over-
expression and release.10,11 Similarly, alteration in the
ECGs-mediated inﬂammatory pathway may be
involved in the pathogenesis of DD.
EGCsareable to interactwithbacteriaanddiscriminate
between pathogens and probiotics via diﬀerent Toll-like
receptors expression and NO production.12 This diﬀerent
response of ECGs and the beneﬁcial role of probiotics
against the gut inﬂammation sustain the hypothesis of a
role of probiotics in the modulation of inﬂammatory
responses in DD induced by pathogen bacteria.
Lactobacillus casei DG

(Lactobacillus paracasei
CNCM I-1572; LCDG), a probiotic strain widely
used in humans, is able to modulate colonic microbiota
in intestinal chronic inﬂammation and it also signiﬁ-
cantly modiﬁes Toll-like receptor expression.13,14
The diﬀerent clinical expressions of DD outcome
(asymptomatic diverticulosis, SUDD, and AD) may be
related to a diﬀerent sensitivity of the colonic mucosa
toward pro-inﬂammatory stimuli. Starting from these
hypothesis, we aimed to evaluate the expression of
NO-related mediators in colonic mucosa of patients
with diverticulosis, SUDD and SUDD with previous
episodes of AD (SUDDþAD), after bacterial infection.
Moreover, we evaluated potential diﬀerences in terms of
basal release of inﬂammatory mediators and whether
LCDG is able to modulate the inﬂammatory response.
Materials and methods
Patients
Biopsies were collected during endoscopy in 40 con-
secutive individuals, divided as follow: 10 patients
with diverticulosis (three women; mean age 70 years,
range 59–77), 10 patients with SUDD (three women,
mean age 63, range 44–92), 10 patients with
SUDDþAD (two women, mean age 60, range 31–77)
and 10 people without gastrointestinal diseases (six
women; mean age 53; range 33–75), who served as con-
trols (CTRLs). Indications for endoscopy were: colo-
rectal cancer screening, adenoma surveillance,
abdominal pain, change of bowel habit, rectorragy.
CTRLs were selected only among individuals undergo-
ing screening for colorectal cancer.
For each patient we collected six random biopsies
taken from the sigma region; in patients with diverti-
cula biopsies were collected close to diverticula.
We obtained informed consent from all the partici-
pants and approval from the ethics committee of the
Federico II University of Naples.
Organ culture of mucosal biopsy specimens
Whole biopsy specimens were placed on a sterilized
metal grid with the mucosal side facing downward and
the serosal side facing upward, to allow a polarization of
the biopsies. The metal grid was put in the middle of a
center-well organ culture dish (BD Europe, Le Pont De
Claix, France) for 24 hours and cultured in Dulbecco’s
modiﬁed Eagle medium (DMEM)-F12, (Sigma-Aldrich,
MO, USA) and kept in an incubator at 37C, continu-
ously gassed with 95% oxygen-5% carbon dioxide.
Biopsies were then stimulated with pathogen and/or a
probiotic bacteria, with the stimulus always added from
the serosal side of the biopsy.
Bacterial strains
Enteroinvasive Escherichia coli (EIEC; ATCC, Rockville,
MD, USA) was chosen for its deleterious eﬀects on the
gastrointestinal tract,15 while L. casei DG (LCDG;
Lactobacillus paracasei CNCM I-1572, Enterolactis,
Sofar S.p.A., Trezzano Rosa, Milan, Italy, deposited
by Sofar at Institute Pasteur of Paris with number
I1572) was chosen for its probiotic eﬀects.14 Bacteria
were cultured and stocked as previously reported.12
Outline of the experiments
Biopsies were treated as shown in Table 1 and super-
natants were collected and biopsies were put in a radio-
immunoprecipitation assay (RIPA) buﬀer (Lonza); both
were stored at –80C for subsequent determinations.
Protein extraction and Western immunoblot
analysis
Western blots were performed and analyzed as previ-
ously described.12 Antibodies used were: rabbit
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anti-iNOS (1:500 vol/vol dilution, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) or mouse anti-
a actin (1:1000 v/v, Santa Cruz).
NO quantification
NO was measured as previously described.12
Enzyme-linked immunosorbent assay (ELISA)
for S100B
ELISA for S100B (Biovendor R&D, Brno, Czech
Republic) was carried out on biopsies supernatants
according to the manufacturer’s protocol.
Statistical analysis
Statistical analysis was performed with analysis of vari-
ance (ANOVA) and multiple comparisons with
Bonferroni’s test. Data presented are meanSD of n
experiments. The level of statistical signiﬁcance was set
at p< 0.05.
Results
Basal levels of the iNOS expression and release of
NO, S100B and cytokines
In diverticulosis patients, iNOS expression was
increased compared to CTRLs, but not to a signiﬁcant
extent (Figure 1(a)). In SUDD and SUDDþAD
patients, basal iNOS expression was signiﬁcantly
increased compared to controls (þ2.04- and þ2.86-
fold increase vs CTRLs, respectively; p< 0.05)
(Figure 1(a)).
In diverticulosis and SUDD patients, NO release
was increased compared to CTRLs, but not to a stat-
istically signiﬁcant extent (Figure 1(b)). In
SUDDþAD, basal NO expression was signiﬁcantly
increased compared to CTRLs (þ7.77-fold increase vs
CTRLs; p< 0.05) (Figure 1(b)).
Because in previous works the enteroglial-derived
S100B protein expression has been linked to NO
release, we analyzed whether S100B was diﬀerently
released in CTRLs and case individuals. As shown in
Figure 1(c), CTRLs, diverticulosis, SUDD and
SUDDþAD showed diﬀerent S100B release but
these diﬀerences were not statistically relevant.
We also analyzed whether interleukin (IL)-1b, IL-6
and IL-10 were diﬀerently released among CTRLs,
diverticulosis, SUDD and SUDDþAD. An increase
in IL-1b release, ranging from CTRL to patients with
previous AD was observed, even if only in the latter
group IL-1b release was signiﬁcantly increased
(þ8.26-fold increase vs CTRL; p< 0.05) (Figure 2(a)).
Regarding IL-6, a trend in an increased release from
CTRL to DD patients was also observed, even if this
was not signiﬁcant (Figure 2(b)). Also for IL-10, an
increased release, ranging from CTRL to
SUDDþAD patients, was observed and also in this
case only in SUDD with previous AD patients IL-10
release was signiﬁcantly greater than CTRLs (þ11.25-
fold increase vs CTRL; p< 0.05) (Figure 2(c)). When
we analyzed the eﬀects of bacteria stimulation on cyto-
kines release in patients aﬀected by every degree of the
pathology, our data were characterized by a high
Table 1. Outlines of experiments.
0h  2.5h                                                                                  24h 
BASAL (medium alone)  
EIEC    +EIEC  
EIEC + LCDG  + EIEC  + LCDG  
LCDG + EIEC  +LCDG  + EIEC  
EIEC and LCDG  +EIEC and LCDG  
h: hours; EIEC: Enteroinvasive Escherichia coli; LCDG: Lactobacillus casei DG.
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variability and no signiﬁcant results were obtained
(data not shown).
Effects of bacteria stimulation on iNOS expression
After analyzing basal levels, in order to evaluate
whether bacteria stimulation diﬀerently modulated
inﬂammatory mediators in CTRL and case individuals,
we evaluated iNOS expression in mucosal biopsies.
In CTRLs, EIEC stimulation signiﬁcantly increased
iNOS expression (þ2.11-fold increase vs basal; p< 0.05,
Figure 3(a)). When LCDG was added before and after
EIEC, no signiﬁcant changes in iNOS expression were
observed (Figure 3(a)), but when LCDG was added at
the same time as EIEC, we observed a signiﬁcant reduc-
tion of iNOS expression compared to that induced by
EIEC alone (–1.50-fold decrease vs EIEC; p< 0.05)
(Figure 3(a)).
In patients with diverticulosis, EIEC signiﬁcantly
increased iNOS expression (þ2.86-fold increase vs
basal; p< 0.05) (Figure 3(b)). When LCDG was
added to biopsies before, after or together with EIEC,
iNOS expression results were signiﬁcantly decreased
compared to EIEC stimulation (–1.59-, –1.79- and
þ1.61-fold decrease vs EIEC, respectively; p< 0.05)
(Figure 3(b)).
In SUDD patients, iNOS expression was signiﬁ-
cantly increased by EIEC stimulation (þ2.14-fold
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Figure 1. Basal iNOS expression and NO and S100B release in patients and healthy individuals. (a) Western blot analysis of basal iNOS
expression in colonic mucosa of patients with diverticulosis, SUDD and SUDD with previous episodes of AD (SUDDþ AD). (b) NO release
determined by Griess assay in colonic mucosa of patients with diverticulosis, SUDD and SUDD with previous episodes of AD (SUDDþ AD).
(c) S100B release determined by ELISA assay in colonic mucosa of patients with diverticulosis, SUDD and SUDD with previous episodes of
AD (SUDDþ AD). All results are expressed as mean SEM of n¼ 10 experiments performed in triplicate. * p< 0.05 vs CTRL. iNOS:
inducible nitric oxide synthase; NO: nitric oxide; SUDD: symptomatic uncomplicated diverticular disease; AD: acute diverticulitis; OD:
optical density; ELISA: enzyme-linked immunosorbent assay; CTRL: control.
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Figure 2. Basal cytokines release from colonic mucosa of patients and healthy individuals. Basal (a) IL-1b, (b) IL-6 and (c) IL-10 release
determined by ELISA assay in colonic mucosa of patients with diverticulosis, SUDD and SUDD with previous episodes of AD (SUDDþ AD).
All results are expressed as mean SEM of n¼ 10 experiments performed in triplicate. * p< 0.05 vs CTRL. IL: interleukin; ELISA: enzyme-
linked immunosorbent assay; SUDD: symptomatic uncomplicated diverticular disease; AD: acute diverticulitis; CTRL: control.
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increase vs basal; p< 0.05) (Figure 3(c)). LCDG add-
ition before or after EIEC resulted in decreased iNOS
expression compared to EIEC stimulation (–2.01- and –
1.50-fold decrease vs EIEC, respectively; p< 0.05)
(Figure 3(c)). When EIEC and LCDG were added con-
temporaneously, iNOS expression was decreased, even
if not to a signiﬁcant extent. Also in SUDDþAD,
EIEC induced a signiﬁcant increase in iNOS expression
(þ2.50-fold increase vs basal; p< 0.05) (Figure 3(d)).
When LCDG was added to biopsies before or after
EIEC, iNOS expression was not signiﬁcantly reduced
compared to EIEC (Figure 3(d)). Conversely, when
EIEC and LCDG were added at the same time, iNOS
expression was signiﬁcantly decreased compared to
EIEC stimulation (–1.73-fold decrease vs EIEC;
p¼NS) (Figure 3(d)).
In all participants analyzed, LCDG alone did not
signiﬁcantly modify iNOS expression (data not shown).
Effect of bacteria stimulation on NO release
In CTRLs EIEC stimulation signiﬁcantly increased NO
release (Figure 4(a)). When LCDG was added to biop-
sies before, after or together with EIEC, NO release
was not diﬀerent from basal level (Figure 4(a)).
Similarly, in patients with AD and with SUDD
(Figure 4(b) and 4(c)), EIEC stimulation signiﬁcantly
increased NO release, whereas no increase of NO
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Figure 3. iNOS expression in patients and healthy individuals after bacteria stimulation. Western blot analysis of iNOS expression after 24
hours of stimulation with enteroinvasive Escherichia coli (EIEC) and or L. casei DG (Lactobacillus paracasei CNCM I-1572; LCDG) in colonic
mucosa of (a) healthy controls, (b) patients with diverticulosis, (c) SUDD and (d) SUDD with previous episodes of AD (SUDDþ AD).
EIECþ LCDG: LCDG added 2.5 hours after EIEC; LCDGþ EIEC: EIEC added 2.5 hours after LCDG; EIEC and LCDG: EIEC and LCDG added
contemporaneously. All results are expressed as mean SEM of n¼ 10 experiments performed in triplicate. *p< 0.05 vs CTRL; ** p< 0.05
vs EIEC. iNOS: inducible nitric oxide synthase; SUDD: symptomatic uncomplicated diverticular disease; AD: acute diverticulitis; CTRL:
control; a.u.: arbitrary units.
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release was observed when LCDG was added to biop-
sies before, after or together with EIEC. Rather, in
patients with diverticulosis, when LCDG was added
before EIEC, we observed a signiﬁcant reduction in
NO release (–2.35-fold decrease vs EIEC; p< 0.05)
(Figure 4(b)).
In SUDDþAD, basal NO release was higher com-
pared to other groups (Figure 4D). In this setting,
EIEC stimulation does not signiﬁcantly increase NO
release (Figure 4D). Similarly, no diﬀerences in terms
of NO release were observed when LCDG was added to
biopsies before, after or together EIEC (Figure 4D).
In all individuals analyzed, LCDG alone did not sig-
niﬁcantly modify NO release (data not shown).
Effect of bacteria stimulation on S100B release
In CTRLs, EIEC induced a signiﬁcant increase in
S100B release (þ2.76-fold increase vs basal; p< 0.05)
(Figure 5(a)). When LCDG was added together with
EIEC, S100B release results were signiﬁcantly
decreased compared to EIEC stimulation (–2.90-fold
decrease vs EIEC; p< 0.05) (Figure 5(a)).
Regarding diverticulosis, SUDD and SUDDþAD
patients, bacteria stimulation did not induce signiﬁcant
changes in S100B release (Figure 5(b), 5(c) and 5(d)).
Moreover, when LCDG alone was added to biop-
sies, nonsigniﬁcant changes in S100B release were
observed (data not shown).
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Figure 4. NO release in patients and healthy individuals after bacteria stimulation. NO release, determined by Griess assay, after 24 hours
of stimulation with enteroinvasive Escherichia coli (EIEC) and/or L. casei DG (Lactobacillus paracasei CNCM I-1572; LCDG) in colonic
mucosa of (a) healthy controls, (b) patients with diverticulosis, (c) SUDD and (d) SUDD with previous episodes of AD (SUDDþ AD).
EIECþ LCDG: LCDG added 2.5 hours after EIEC; LCDGþ EIEC: EIEC added 2.5 hours after LCDG; EIEC and LCDG: EIEC and LCDG added
contemporaneously. All results are expressed as mean SEM of n¼ 10 experiments performed in triplicate. * p< 0.05 vs CTRL; **
p< 0.05 vs EIEC. NO: nitric oxide; SUDD: symptomatic uncomplicated diverticular disease; AD: acute diverticulitis; CTRL: control; a.u.:
arbitrary units.
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Discussion
Our results showed an activation of NO-dependent
inﬂammation related to iNOS expression and NO
release that appeared progressively increased from
diverticulosis to SUDD with previous diverticulitis.
In addition, we showed a diﬀerent response of the
colonic mucosa of these patients to infectious stimuli
and a role of the probiotic LCDG in preventing these
eﬀects.
NO is an important mediator of direct and indirect
smooth muscle relaxation of the wall bowel.17 NO is
also involved in gut inﬂammation and in the antibac-
terial response.18 Previous studies have demonstrated
an increase in endogenously NO-mediated responses
in patients with diverticulosis19 and abnormal nitrergic
activities and an alteration in NOS activity in the gut of
patients with SUDD.20,21 Longitudinal muscle shows
abnormal relaxation responses to NO and contains
altered levels of iNOS in uncomplicated DD.21
While previous studies usually focused their atten-
tion only on a single set of patients—those with diver-
ticulosis rather than patients with SUDD or previous
AD—in our ﬁrst set of experiments, we sought to deter-
mine whether an increase in the severity of the disease
matched an increase in the iNOS expression and NO
release from the colonic mucosa of patients with a dif-
ferent grade of DD. Our data conﬁrmed this hypoth-
esis, as in colonic mucosal biopsies iNOS expression
was about 1.5-fold higher in patients with diverticu-
losis, two-fold higher in patients with SUDD and
about three-fold higher in patients with previous AD,
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Figure 5. S100B release in patients and healthy individuals after bacteria stimulation. S100B release, determined by ELISA assay, after 24
hours of stimulation with enteroinvasive Escherichia coli (EIEC) and/or L. casei DG (Lactobacillus paracasei CNCM I-1572; LCDG) in colonic
mucosa of (a) healthy controls, (b) patients with diverticulosis, (c) SUDD and (d) SUDD with previous episodes of AD (SUDDþ AD).
EIECþ LCDG: LCDG added 2.5 hours after EIEC; LCDGþ EIEC: EIEC added 2.5 hours after LCDG; EIEC and LCDG: EIEC and LCDG added
contemporaneously. All results are expressed as mean SEM of n¼ 10 experiments performed in triplicate. * p< 0.05 vs CTRL; **
p< 0.05 vs EIEC. ELISA: enzyme-linked immunosorbent assay; SUDD: symptomatic uncomplicated diverticular disease; AD: acute diver-
ticulitis; CTRL: control; a.u.: arbitrary units.
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compared to CTRLs. These data indicate the presence
of an ‘‘inﬂammatory nitrergic gradient,’’ going from
CTRLs to patients with SUDD and previous AD.
In fact, it is known that while NO is physiologically
released on demand for short periods of time following
activation of constitutively expressed endothelial NO
synthase (eNOS) or neuronal NO synthase (nNOS),
iNOS expression is induced only after cell activation
and produces NO for long periods of time, in a patho-
physiological, inﬂammatory, context.22 Our data match
previous reports that show that the immune cell inﬁl-
trates in colonic mucosa are increased according to dis-
ease severity.23
The presence of this inﬂammatory gradient appears
further conﬁrmed by the analysis of basal cytokine
release from the colonic mucosa of our patients.
Indeed, our data show an overall increase in the release
of IL-1b, IL-6 and IL-10 that goes in parallel with the
increase in the grade of disease severity.
We also evaluated basal NO release from colonic
biopsies and we found that it was about four-fold
higher in patients with diverticulosis and SUDD and
eight-fold higher in patients with previous AD than in
CTRLs. The diﬀerences in iNOS expression and NO
release between diverticulosis and SUDD patients are
unclear, but, as proposed by other authors, it may be
due to a diﬀerent and altered nitrergic neuro-muscular
transmission in these two subsets of patients,19,21 where
other than iNOS, nNOS also has a major role in pro-
ducing NO.
Considering that colonic mucosa of CTRLs and
patients showed basal diﬀerences in expression and
release of NO-related mediators and that changes in
gastrointestinal microﬂora are hypothesized to inﬂu-
ence the etiology of DD,24,25 we asked whether the
colonic mucosa of these patients also had a diﬀerent
‘‘sensitivity’’ toward pathogenic and non-pathogenic
bacteria stimuli. We found that, after a challenge with
the pathogenic bacteria EIEC, iNOS expression was
signiﬁcantly higher than baseline, both in CTRLs and
patients. Conversely, when the biopsies were challenged
with the probiotic LCDG no signiﬁcant increase com-
pared to baseline was observed. To determine a possible
preventive or healing eﬀect of the probiotic, it was
added to biopsies before, after or together with EIEC.
Even with some diﬀerences among the diﬀerent sets of
patients, the presence of LCDG counteracted the
increase in iNOS expression induced by EIEC. We
also analyzed NO release and we obtained similar
results as iNOS, with the diﬀerence that in patients
with previous AD, EIEC-induced NO increase did
not reach a statistical signiﬁcant extent. This may prob-
ably be due to an already high baseline NO level, which
does not allow for the appreciation of any changes
induced by further bacterial stimulation. Taken
together these data point out a diﬀerent reactivity of
the mucosa of patients aﬀected by every degree of the
pathology toward pathogenic stimulation and a role of
probiotics in counteracting these eﬀects. Although the
exact mechanisms of action exerted by the probiotic are
unclear, the observation that LCDG appears eﬀective
in decreasing EIEC-induced iNOS expression and NO
release further support previous reports indicating pro-
mising eﬀects of probiotics’ use in DD.13
In recent years, various studies found an association
between distinct abnormalities of the ENS and EGC
and the disturbed motility patterns underlying DD.
Patients with diverticulitis showed decreased EGC
and interstitial cells of Cajal density and S100B immu-
noreactivity in myenteric ganglia.26 Although the over-
all glial cell density was reduced in DD, a study in 2010
showed that a subgroup of myenteric ganglia displayed
bulbous protrusions almost exclusively composed of
glial cells,27 but this reported EGC activation phenom-
enon has not yet been conﬁrmed by other investiga-
tions. We previously reported that the EGCs-derived
S100B protein—a pivotal signaling molecule that par-
ticipates in the onset and progression of the inﬂamma-
tory status in the gut—regulates NO production via
iNOS interaction.11 For this reason we also evaluated
the involvement of S100B in DD. Analyzing basal
S100B expression, no statistically signiﬁcant diﬀerences
between CTRLs and patients were found, even if a
trend toward reduced S100B expression was evident
in patients with previous diverticulitis. In CTRLs, sti-
mulating biopsies with EIEC, but not with LCDG, sig-
niﬁcantly increased S100B expression. LCDG also
exerted a preventive and healing eﬀect because when
biopsies were co-stimulated with EIEC and LCDG,
the EIEC-induced S100B increase was not evident.
Instead, considering biopsies of patients aﬀected by
various grade of diverticulitis, bacteria stimulation
exerted no signiﬁcant eﬀects on S100B expression.
Considering our data, S100B seems not to be involved
in NO production. Nevertheless, in view of previous
studies,28 involvement of EGC in this pathology can
neither be conﬁrmed nor excluded.
In conclusion, we showed that the colonic mucosa of
patients aﬀected by diverticulosis, SUDD and previous
AD is basally characterized by dissimilar levels of iNOS
expression and NO release and that these levels increase
with the degree of disease severity. We also showed that
colonic mucosa of patients with diﬀerent grades of DD
has a diﬀerent reactivity toward pathogenic stimuli and
that the LCDG may be eﬀective in counteracting the
inﬂammatory eﬀects exerted by EIEC. Changes in gut
microbiota have been reported to occur in patients with
symptomatic DD;29 for this reason, adjusting the gut
microbiota by the use of probiotics could inﬂuence the
natural history of the disease. These data further
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support the beneﬁcial role of LCDG in an inﬂamma-
tory context, as previously reported.14
Our preliminary data may lay the basis for further
studies addressing the concept of a diﬀerent reactivity
of the mucosa of patients with various-grade DD
toward luminal stimuli and for addressing, in a large-
scale cohort study, the real eﬀectiveness of probiotic
therapy in prevention of diverticulitis. Studies further
addressing the relation between EGCs and DD are war-
ranted to better understand the pathophysiology of this
disease and to eventually lead innovative therapeutic
approaches to DD.
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